www.bioscience.co.uk
Sales & Support: +44 (0)1223 316 855

*

C3b/iC3b, Human, mAb 5G9

Catalogue number:
HM2285-100UG
Supplier:
Size:
100 µg _$$_
Product is available in:
  • UK
  • Ireland
  • Europe
  • USA
  • Rest of World
£505.00 Shipping is calculated in checkout
Applications:

Functional studies

Product Description:

The monoclonal antibody 5G9 recognizes Complement Factor C3b/iC3b, it specifically binds human C3 as well as the breakdown products C3b and iC3b. C3 plays a central role in the activation of the complement system. Its activation is required for both classical and alternative complement activation pathways. People with C3 deficiency are susceptible to bacterial infection.One form of C3-convertase, also known as C4b2a, is formed by a heterodimer of activated forms of C4 and C2. It catalyzes the proteolytic cleavage of C3 into C3a and C3b, generated during activation through the classical pathway as well as the lectin pathway. C3a is an anaphylotoxin and the precursor of some cytokines such as ASP, and C3b serves as an opsonizing agent. Factor I can cleave C3b into C3c and C3d, the latter of which plays a role in enhancing B cell responses. In the alternative complement pathway, C3 is cleaved by C3bBb, another form of C3-convertase composed of activated forms of C3 (C3b) and factor B (Bb). Once C3 is activated to C3b, it exposes a reactive thioester that allows the peptide to covalently attach to any surface that can provide a nucleophile such as a primary amine or a hydroxyl group. Activated C3 can then interact with factor B. Factor B is then activated by factor D, to form Bb. The resultant complex, C3bBb, is called the alternative pathway (AP) C3 convertase.C3bBb is deactivated in steps. First, the proteolytic component of the convertase, Bb, is removed by complement regulatory proteins having decay-accelerating factor (DAF) activity. Next, C3b is broken down progressively to first iC3b, then C3c + C3dg, and then finally C3d. Factor I is the protease that performs these cuts with CR1 as cofactor. Clone 5G9 recognize separate, non-overlapping epitopes on C3 fragments. Levels of C3 in the blood may be measured to support or refute a particular medical diagnosis. For example, low C3 levels are associated with some types of kidney disease such as post-infectious glomerulonephritis and shunt nephritis.

Details Cat number & supplier Size Price
C5, Mouse, mAb BB5.1 HM1073-100MG · Hycult Biotech
HM1073-100MG
Hycult Biotech
100 mg £43847.00
100 mg
view
Activated C3, Human, mAb I3/15 HM2257-100UG · Hycult Biotech
HM2257-100UG
Hycult Biotech
100 µg £316.00
100 µg
view
Properdin, Human, mAb 1G6D2 HM2354-100UG · Hycult Biotech
HM2354-100UG
Hycult Biotech
100 µg £410.00
100 µg
view
C5/C5a, Human, mAb 561 HM2076-100UG · Hycult Biotech
HM2076-100UG
Hycult Biotech
100 µg £410.00
100 µg
view
C3/C3a, Human, mAb 2898 HM2075-100UG · Hycult Biotech
HM2075-100UG
Hycult Biotech
100 µg £410.00
100 µg
view
C3a/C3a des Arg, Human, mAb 2991 HM2074-100UG · Hycult Biotech
HM2074-100UG
Hycult Biotech
100 µg £410.00
100 µg
view
C3c, Human, mAb F1-4 HM2318-100UG · Hycult Biotech
HM2318-100UG
Hycult Biotech
100 µg £452.00
100 µg
view
C3b/iC3b, Human, mAb 3E7 HM2286-100UG · Hycult Biotech
HM2286-100UG
Hycult Biotech
100 µg £505.00
100 µg
view
C9 neoantigen, Human, mAb WU13-15 HM2264-100UG · Hycult Biotech
HM2264-100UG
Hycult Biotech
100 µg £452.00
100 µg
view
C4d, Human, mAb 7H4 HM2230-100UG · Hycult Biotech
HM2230-100UG
Hycult Biotech
100 µg £452.00
100 µg
view